Clinical Trial Update: A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

This document summarizes a completed safety and tolerability study of intracerebroventricular administration of sNN0031 in Parkinson's disease patients. It cove…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• sNN0031

Snippet

Sponsor: Newron Sweden AB | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED